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Role of vitamin D deficiency in type 2  
diabetes: Association or coincidence?
ABSTrACT
Background. Vitamin D has received considerable at-
tention for its possible role in myriad of clinical condi-
tions especially non-communicable chronic diseases. 
however, it is the role in the pathogenesis of type 2 
diabetes (T2DM), which has generated a lot of enthu-
siasm to unravel the association between the two.
Aim. To determine the prevalence of hypovitaminosis D 
and its relation with the glycemic control in T2DM 
patients attending a tertiary care hospital in Kashmir.
Methods. A total of 108 cases of T2DM and 101 healthy 
controls aged between 35-65years were investigated in 
this study. 25-hydroxyvitamin D (25OHD), glycosylated 
hemoglobin (hbA1c) and fasting serum insulin levels were 
determined using standardised and automated assays. 
insulin resistance (ir) and beta-cell function (B) were es-
timated by the homeostasis model assessment (hOMA).
results. The mean serum level of 25OhD was sig-
nificantly lower in T2DM group compared to controls 
(20.55 ± 12.27 vs 27.62 ± 5.32 ng/mL; P = 0.001). The 
prevalence of hypovitaminosis D was significantly high-
er in patients with T2DM (79.5% vs 62.7%; P = 0.031). 
Overall 51.1% and 28.4% patients with diabetes and 
41.2% and 21.6% controls had vitamin D deficiency 
and insufficiency respectively.
Vitamin D was found to have a significantly positive as-
sociation with serum fasting insulin level and hOMA-B 
in both cases (P = 0.019), (P = 0.026) and controls 
(P = 0.022), (P = 0.008) respectively. Prolonged gly-
cemic control as determined by hbA1c demonstrated 
a significant inverse correlation with vitamin D level 
in both cases (r = -0.225;P = 0.035) and controls 
(r = -0.373; P = 0.007).
Conclusion. We conclude that vitamin D deficiency 
(VDD) is a very common health problem and is rela-
tively more common in patients with T2DM. There is an 
inversed association between vitamin D and glycemic 
control. Vitamin D status thus appears to affect glucose 
homeostasis. Vitamin D screening and supplementa-
tion is a plausible way to mitigate the impact of VDD 
on glucose homeostasis in T2DM. (Clin Diabetol 2021; 
10; 2: 188–194)
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Introduction
India, one of the fast growing economies of the 
world is witnessing rapid growth of diabetes cases owing 
to improved socioeconomic conditions and is estimated 
to harbor second largest diabetes population of over 77 
million in 2019 in the world, which is expected to increase 
to 134 million in 2045 [1]. Urbanisation of lifestyle pa-
rameters and availability of affordable food items, have 
resulted in escalating prevalence of diabetes not only 
in urban dwellings but also in rural India. Like rest of 
India, in valley of Kashmir also, the prevalence of T2DM 
has shown a substantial increase from 1.89% (1.98% in 
males and 1.77% in females) in 2000, to 6.31% (7.15% 
in urban and 5.5% in rural) reported in a study published 
in 2015 [2, 3]. This enormous increase in prevalence of 
diabetes mellitus (DM) and its associated complications 
has emerged as a major health concern in relation to 
increased morbidity, mortality and impaired quality of 
life associated with the disease [4, 5]. The epidemic 
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proportions of the disease and its sequelae makes it 
imperative to study and find out the modifiable risk fac-
tors associated with DM and to address these factors to 
mitigate the impact of deleterious effects of this disease. 
Apart of non modifiable genetic predisposition there are 
many environmental factors including physical inactivity, 
obesity and poor dietary habits which contribute greatly 
to its development. However, in the recent years role of 
vitamin D, as modifiable risk factor for DM has come 
under careful scrutiny with studies suggesting a possible 
link of VDD in the pathogenesis of T2DM [6, 7].
Vitamin D, a fat soluble vitamin synthesized in 
the skin has been found to have myriad of roles in 
health and disease, with studies implicating its role in 
pathogenesis of number of chronic diseases including 
heart disease, autoimmune diseases, type 2 diabetes, 
many cancers and infectious diseases. High prevalence 
of DM in areas of significant VDD has generated lot of 
enthusiasm in unravelling the relationship between 
the two. The biological evidence implicating potential 
influence of vitamin D on insulin secretion and sensitiv-
ity include the presence of specific vitamin D receptor 
in pancreatic cells and target organs including skeletal 
muscles and adipose tissues in addition to expression 
of 1-a hydroxylase enzyme in pancreatic cells [8–10]. 
The present study aimed to find the prevalence of 
VDD in patients with T2DM attending a tertiary care 
hospital in Srinagar, Kashmir and to examine whether 
25OHD has any clinically significant influence on gly-
cemic control (HbA1c) and insulin resistance (HOMA-IR) 
in patients with T2DM. 
Aims and objectives
To determine the prevalence of hypovitaminosis D 
in patients with T2DM and its correlation with glycated 
hemoglobin (HbA1C), a marker of glycemic control.
Material and methods
Study setting
This was a cross-sectional analytical study carried out 
in the Department of Medicine at Government Medical 
College, Srinagar after obtaining ethical clearance from in-
stitutional ethics committee. The study was carried out over 
a period of 18 months from November 2017 to May 2019. 
The study was done according to the principles expressed 
in the Declaration of Helsinki. A written informed consent 
was obtained from all the subjects, in the language that 
was understandable to the patient and their attendant.
Study population and sample size
A total of 108 cases of T2DM and 101 healthy 
controls aged between 35–65 years attending the OPD 
and wards of this hospital were included in the study.
inclusion criteria
Cases: All patients aged 35–65 years with T2DM 
on oral anti-diabetic medication who gave informed 
consent.
Controls: Apparently healthy individuals aged 
35–65 years who gave informed consent.
Exclusion criteria
Diabetic patients below 35 years or above 65 years, 
subjects with T1DM or other forms of diabetes, pregnant 
women, patients with chronic diseases including chron-
ic liver disease or alanine aminotransferase > 5 times 
upper reference limit, renal insufficiency (glomerular 
filtration rate < 30 mL/min), diarrhoeal or malabsorp-
tion state and tuberculosis.
Methods
25-hydroxyvitamin D level was assayed using the 
chemiluminescent method. HbA1c assay was performed 
on the autoanalyzer (Abbott GmbH & co. kg Max-
Planck-Ring 2. 65205 Wiesbaden, Germany) based on 
the turbidimetric inhibition immunoassay (TINIA) of 
hemolyzed blood samples and the hexokinase method 
was employed for assay of fasting plasma glucose. 
Enzyme-linked immunosorbent assay was used to 
determine the fasting serum insulin levels. Serum 
calcium, phosphorus, albumin and creatinine were 
measured using standardized and automated assays. 
Insulin resistance (IR) and beta-cell function (B) were 
estimated by the homeostasis model of assessment-
insulin resistance index (HOMA-IR) and the homeo-
static model of assessment-beta (HOMA-B) respectively. 
Higher HOMA-IR value indicates greater IR, and a lower 
HOMA-B value indicates greater β-cell dysfunction.
HOMA-IR is defined as the product of fasting se-
rum insulin (µU/mL) and fasting plasma glucose (FPG) 
(mmol/L) divided by 22.5. A score of > 4 defined IR [11].
HOMA-B insulin secretion (IS) defined as the 
product of twenty and fasting insulin (µU/ml) divided 
by FPG (mmol/L) minus 3.5. A score of < 100 defined 
reduced IS (B) [11].
Serum levels of 25OHD were classified endocrine 
society guidelines into deficient (< 20 ng/mL), insuf-
ficient (≥ 20 to < 30 ng/mL) and normal (≥ 30 ng/mL). 
Subsequently, for this study, we considered all 25OHD 
values of < 30 ng/m as hypovitaminosis D both in cases 
and controls.
Statistical analysis
Data was first entered into Microsoft Excel. All sta-
tistical analyses were performed using SPSS (Statistical 
Package for the Social Sciences) version 25.0 software 
from IBM Corporation, NY, United States. The statistical 
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techniques used for analyzing this data were independ-
ent student t-test and one-way ANOVA with multiple 
range tests. Wherever applicable, an appropriate non-
parametric test like Mann Whitney, Kruskal Wallis and 
other tests were used. A P-value of less than 0.05 was 
considered significant.
Results
A total of 108 cases comprising of 51% male 
(n = 55) and 49% female (n = 53) and age matched 
101 controls comprising of 60.8% males (n = 61) and 
39.2% females (n = 40), were included in this study. 
Demographic and laboratory characteristic of the study 
population is shown in the Table 1. 
The mean age and BMI of cases and controls at 
presentation was 48.28 ± 9.53 years vs 48.12 ± 9.35 
years and 25.60 ± 3.59 kg/m2 vs 22.58 ± 1.78 kg/m2 
respectively. The prevalence of hypovitaminosis D was 
significantly higher in patients of T2DM compared to 
controls (79.5% vs 62.8%; P = 0.031). Overall 51.1% 
and 28.4% patients with diabetes and 41.2% and 
21.6% of controls had VDD and insufficiency respec-
tively. The mean serum level of 25OHD was significantly 
lower in T2DM group compared to controls (20.55 
± 12.27 vs 27.62 ± 5.32 ng/mL; P = 0.001). Fasting 
plasma insulin and HOMA-IR values were significantly 
higher in T2DM cases compared to control group 
(12.18 ± 10.28 vs 7.93 ± 4.74 mIU/L; P = 0.006) and 
(5.62 ± 6.42 mg/dl vs 1.61 ± 0.82 mg/dl; P = 0.000). 
However, HOMA-B was significantly higher in control 
group compared to T2DM patients (30.65 ± 24.48 vs 
22.88 ± 24.16; P = 0.000). On sub analysis of diabe-
tes group (Table 2), comparison of patients with good 
glycemic control (HbA1c < 7%) with those of poor 
glycemic control (HbA1c ≥ 7) revealed fasting insulin 
levels and HOMA-B were significantly higher (14.99 ± 
12.54 mg/dl vs 10.23 ± 7.94 mg/dl; P = 0.032) and 
(32.33 ± 31.80 vs 16.34 ± 13.98; P = 0.002) in good 
glycemic group compared to those in poor glycemic 
group. Similarly 25OHD level was significantly higher 
in patients with good glycemic control (24.69 ± 12.17 
ng/mL vs 17.68 ± 11.60 ng/mL; P = 0.008). The preva-
lence of hypovitaminosis D was significantly higher in 
patients with poor glycemic control (88.4% vs 66.7%; 
P = 0.013), with patients having significantly higher 
VDD (61.5% vs 36.1%; P = 0.019).
There was a significant inverse relationship be-
tween vitamin D and serum fasting blood glucose in 
control group (r = -0.402; P = 0.003) (Table 3). While 
it was inversely related but not statistically significant 
Table 1. Demographic and laboratory parameters of cases and controls.
Variable Cases (n = 108) 
Mean ± SD (95% Ci)
Controls (n = 101)  
Mean ± SD (95% Ci)
P value
Age [Years] 48.28 ± 9.53 (46.26–50.30) 48.12 ± 9.35 (45.49–50.75) 0.921
BMI [Kg/m2] 25.60 ± 3.59 (24.84–26.36) 22.58 ± 1.78 (22.08–23.08) 0.000*
Waist  to hip ratio 1.03 ± 0.87 (0.84–1.21) 0.86 ± 0.03 (0.85–0.87) 1.66
Fasting plasma glucose [mg/dl] 181.23 ± 72.82 (165.80–196.66) 88.93 ± 16.76 (84.22–93.65) 0.000*
Cholesterol [mg/dl] 188.31 ± 68.46 (173.80–202.81) 139.63 ± 6.55 (122.31–156.94) 0.000*
Triglycerides [mg/dl] 255.97 ± 165.37 (220.93–291.01) 201.22 ± 140.92 (161.58–240.85) 0.049*
HDL [mg/dl] 44.26 ± 14.87 (41.10–47.41) 57.51 ± 18.56 (52.29–62.72) 0.000*
LDL [mg/dl] 102.44 ± 44.27 (93.00–111.88) 69.94 ± 22.36 (63.65–76.23) 0.000*
Calcium [mg/dl] 8.85 ± 0.79 (8.68–9.01) 8.89 ± 0.66 (8.70–9.07) 0.739
Phosphorus [mg/dl] 3.59 ± 0.98 (3.38–3.80) 3.28 ± 0.65 (3.10–3.47) 0.044*
Albumin [mg/dl] 4.15 ± 0.63 (4.02–4.29) 3.98 ± 0.61 (3.80–4.15) 0.110
Fasting insulin [IU/mL] 12.18 ± 10.28 (10.01–14.36) 7.93 ± 4.74 (6.60–9.27) 0.006*
HOMA-IR 5.62 ± 6.42 (4.26–6.98) 1.61 ± 0.82 (1.38–1.85) 0.000*
HOMA-B 22.88 ± 24.16 (17.76–28.00) 30.65 ± 24.48 (23.76–37.53) 0.000*
Vitamin D [ng/mL] 20.55 ± 12.26 (17.95–23.14) 27.61 ± 5.32 (23.30–31.92) 0.001*
HbA1C % 8.48 ± 2.54 (7.94–9.02) 5.08 ± 0.61 (4.90–5.25) 0.003*
Vitamin D deficiency % [n] 51.1 (55) 41.2 (41) 0.257
Vitamin D insufficiency % [n] 28.4 (31) 21.6 (22) 0.375
Hypovitaminosis D % [n] 79.5 (86) 62.8 (63) 0.031*
Categorical data are shown as %; continuous variables are shown as mean ± standard deviation. *Significance. HDL — high density lipoproteins, LDL — 
low density lipoproteins; HbA1C — glycosylated hemoglobin; HOMA-IR — homeostasis model of assessment-insulin resistance index; HOMA-B — homeosta-
sis model of assessment- beta; CI — confidence interval; n — number of patients
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in diabetic group (r = −0.019; P = 0.857). We found 
a significant positive association between serum fasting 
insulin level and vitamin D in both cases (r = 0.250; 
P = 0.019) and controls (r = 0.319; P = 0.022). Similarly 
there was a significant positive association between 
vitamin D and HOMA-B in both cases (r = 0.237; 
P = 0.026) and controls (r = 0.370; P = 0.008), how-
ever, there was no correlation between vitamin D 
status and HOMA-IR in diabetes patients (r = 0.172; 
P = 0.109) as well as in healthy control (r = 0.280; 
P = 0.056). We found a significant inverse correla-
tion between serum 25OHD level and HbA1c in both 
cases (r = -0.225; P = 0.035) and controls (r = -0.373; 
P = 0.007) (Figure 1, 2).
Discussion
Vitamin D deficiency is a global health problem af-
fecting almost all the countries of the world including 
India, with studies estimating the community preva-
lence of 50% to 94% [12]. Similarly a very high preva-
lence of vitamin D inadequacy was demonstrated in 
apparently healthy, young, and non-pregnant adults of 
Kashmir region in northern India [13] aged 18–40 years. 
Of the 92 healthy natives including 64 men and 28 
non-pregnant/non-lactating women, aged 18–40 years, 
83% had VDD with 25%, 33%, and 25% having mild, 
moderate, and severe deficiency, respectively. The pres-
ence of high prevalence of both VDD and T2DM in the 
Kashmir valley and evidence linking VDD with variety of 
chronic diseases including T2DM prompted us to take 
up this study to find the link between the two major 
health problems.
Insulin resistance and or action and impaired insu-
lin secretion are the main significant factors involved 
in the pathogenesis of T2DM though other distinct 
pathophysiologic abnormalities commonly referred as 
Table 2. Comparative analysis of demographic characteristics and biochemical parameters in diabetic patients with good 
and poor glycemic control
Variables good glycemic control (n = 45)  
(95% Ci)
Poor glycemic control (n = 63) 
(95% Ci)
P value
Age [years 47.61 ± 9.47 (44.41–50.81) 48.75 ± 9.64 (46.06–51.44) 0.585
Fasting plasma glucose [mg/dl] 158.53 ± 60.07 (138.20–178.85) 196.94 ± 77.17 (175.46–218.43) 0.014*
Cholesterol [mg/dl] 187.83 ± 88.14 (158.01–217.65) 188.63 ± 51.62 (174.26–203.01) 0.957
Triglyceride [mg/dl] 253.17 ± 166.21 (196.93–309.41) 257.90 ± 166.39 (211.58–304.23) 0.896
HDL [mg/dl] 44.03 ± 16.50 (38.44–49.61) 44.42 ± 13.80 (40.58–48.26) 0.904
LDL [mg/dl] 104.69 ± 55.63 (85.87–123.52) 100.85 ± 34.62 (91.11–110.60) 0.692
Fasting insulin [IU/mL] 14.99 ± 12.54 (10.75–19.24) 10.23 ± 7.94 (8.01–12.44) 0.032*
HOMA-IR 6.19 ± 6.25 (4.08–8.30) 5.23 ± 6.56 (3.40–7.05) 0.493
HOMA-B 32.33 ± 31.80 (21.57–43.09) 16.34 ± 13.98 (12.45–20.24) 0.002*
Vitamin D [ng/mL] 24.69 ± 12.17 (20.57–28.80) 17.68 ± 11.60 (14.46–20.91) 0.008*
HbA1C% 6.37 ± 0.45 (6.22–6.53) 9.94–2.37 (9.28–10.60) 0.000*
Vitamin D Deficiency % 36.1(16) 61.5 (40) 0.019*
Vitamin D insufficiency % 30.6(14) 26.9(17) 0.71
Hypovitaminosis D % 66.7(30) 88.4 (57) 0.013* 
Categorical data are shown as %; continuous variables are shown as mean ± standard deviation. *Significant. TG — triglycerides, HDL — high density 
lipoproteins; LDL — low density lipoproteins; HbA1C — glycosylated hemoglobin; HOMA-IR — homeostasis model of assessment-insulin resistance index; 
HOMA-B — homeostasis model of assessment-beta; CI — confidence interval; n — number of patients
Table 3. Correlation of vitamin D with various parameters 
in cases and controls 
Variables Cases Control
Pearson P value Pearson P value
BMI 0.171 0.111 -0.163 0.253
WHR 0.049 0.648 -0.047 0.741
FPG -0.019 0.857 -0.402 0.003*
Cholesterol 0.035 0.747 -0.235 0.097
Triglycerides -0.159 0.140 -0.148 0.300
HDL -0.193 0.072 0.019 0.896
LDL 0.204 0.056 0.224 0.114
HbA1c -0.225 0.035* -0.373 0.007*
FI 0.250 0.019* 0.319 0.022*
HOMA-IR 0.172 0.109 0.280 0.056
HOMA-B 0.237 0.026* 0.370 0.008*
*Significant. HDL — high density lipoproteins; LDL — low density lipopro-
teins; HbA1C — glycosylated hemoglobin; BMI — body mass index; WHR 
— waist hip ratio; FPG — fasting plasma glucose; FI — fasting insulin; 
HOMA-IR — homeostasis model of assessment-insulin resistance index; 
HOMA-B — homeostasis model of assessment- beta
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“Ominous Octet” have been associated with T2DM. 
Vitamin D has been found to influence these mecha-
nisms and has been suggested to play an important role 
in modulating impaired pancreatic beta cell function, 
insulin resistance and systemic inflammation, seen in 
patients with T2DM [14]. Vitamin D has been implicated 
to have beneficial effect on insulin sensitivity through 
various mechanisms including, directly acting on in-
sulin receptors [15], thus improving glucose transport 
across the cells in the target tissues and by activating 
peroxisome proliferator activator receptor-d thereby 
regulating fatty acid metabolism [16] in addition to 
affecting the calcium homeostasis [17]. Similarly vitamin 
D has been found to have beneficial effects on insulin 
release by acting directly on vitamin D receptor in b-
cells and vitamin D-dependent calcium-binding proteins 
[18] and indirectly via regulation of calcium transport 
through b-cells [19].
The present study is the first study on the relation-
ship between type 2 DM and 25OHD in the Kashmir 
valley of Northern India. In the current study, mean 
age of patients with T2DM and controls was 48.28 ± 
9.535, and 48.12 ± 9.354 years respectively.
The prevalence of VDD and insufficiency in T2DM 
patients in the current study was 51.1% and 28.4% 
respectively, whereas the prevalence of VDD and vi-
tamin D insufficiency in healthy controls was 41.2% 
and 19.6% respectively. Despite the high prevalence of 
hypovitaminosis D (< 30 ng/mL) in the studied popula-
tion it was significantly pronounced in patients with 
T2DM (79.5%) compared to healthy controls (60.8%). 
On further analysis it was found that VDD was more 
prevalent in diabetic patients with poor glycemic con-
trol compared to those with good glycemic control. 
The presence of comparatively higher prevalence of 
hypovitaminosis D in diabetic patients in general and 
in patients with poor glycemic control in particular is 
in agreement with the results documented in previous 
studies from Asian countries [20–22].
The main source of Vitamin D is skin exposure to 
ultraviolet B radiation (UVB) from the sun however, di-
etary and supplemental intake, lifestyle and underlying 
health conditions also influence the vitamin D status 
of the body [23]. The higher levels of VDD in patients 
of T2DM could be because of relatively limited sun 
exposure on account of limited physical activity and 
presence of obesity in diabetes in addition to impaired 
conversion of precursors of vitamin D in liver and kid-
neys in the presence of liver disease and nephropathy. 
Large number of observational studies across the world 
have demonstrated an inverse association of serum 
levels of 25OHD and HbA1c supporting a possible active 
role of VDD in pathogenesis of T2DM. NHANES analysis 
of 9,773 adults who participated in the 2003–2006 
NHANES, found that serum 25OHD concentration was 
inversely associated with HbA1c level in individuals 
35–74 years old, but not among the younger or older 
adults [24]. Our study like other observational studies 
also demonstrated a significant inverse correlation 
between Vitamin D levels and HbA1c levels which is in 
agreement with results documented in the literature 
[20, 22, 24, 25]. Patients with VDD have been found 
to have higher HbA1c, a marker of prolonged glycemic 
control, however, some authors suggest that vitamin D 
may be a marker of general health and its association 
with T2DM may be a coincidence [26]. Observational 
nature of these studies did not provide a conclusive 
evidence for any possible cause and effect relationship 
between VDD and type 2 diabetes mellitus. Despite suf-
ficient evidence for possible association in observational 
studies, Interventional studies have been inconclusive 
Figure 1. Scatter plot between vitamin D and HbA1c of cases
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to address the nature of relationship between the two. 
Lack of conclusive evidence of association between the 
two have given credence to the observation that a low 
serum 25OHD level might be the result of poorer health 
or even worse metabolic control of diabetes. 
One of the observations of our study was the 
inverse association of serum vitamin D levels with 
fasting plasma glucose in patients of T2DM; however 
the relation was not statistically significant. The rea-
son for statistically insignificant relation for the cases 
could be the adequate treatment by oral anti-diabetic 
medications. This observation was consistent with re-
sults from a study by Kumar et al. who observed that 
vitamin D level was inversely related to fasting blood 
sugar in patients with T2DM [22]. We also found that 
the fasting plasma glucose levels of healthy controls 
had significant inverse relation with serum vitamin D 
levels. This is similar to the conclusion drawn from a 
meta-analysis which showed that there was an overall 
inverse association of vitamin D status and fasting 
plasma glucose in the non-diabetic population [22, 27]. 
This relationship of vitamin D with plasma glucose level 
suggested that hypovitaminosis D is associated with 
increased risk of hyperglycemia both in diabetic and 
non-diabetic subjects. We found a significant positive 
association between serum fasting insulin level and 
vitamin D in both cases and controls, which is similar to 
results demonstrated in an earlier study where authors 
concluded that vitamin D is positively associated with 
insulin levels [28]. HOMA-B represents insulin secretory 
capacity of pancreatic beta cells and thus the higher 
the value the more the beta-cells have to secrete in-
sulin to handle existing blood glucose level. VDD has 
been found to inhibit insulin secretion by modulating 
VDR on pancreatic beta cells. Our study demonstrated 
a significant positive association between vitamin D 
levels and HOMA-B in both cases and controls thus 
highlighting the importance of vitamin D in insulin 
secretion. In the current study we did not found any 
significant correlation between serum vitamin D levels 
and HOMA-IR levels in both the control group and the 
diabetic patients. The lack of association between the 
vitamin D levels and HOMA-IR is consistent with the 
results demonstrated in earlier studies  [25, 29, 30].
limitations of the study
The present study has several limitations. Ob-
servational nature of present study prevents us from 
making any conclusive observation as far as any cause 
and effect relationship between VDD and T2DM is 
concerned. The study sample was relatively too small 
to project the results to whole population to draw any 
conclusive inference.
Summary and conclusion
We conclude that the prevalence of hypovitamino-
sis D is very common; however, in patients with T2DM, it 
is relatively more common compared to non-diabetics. 
We also found that there is an inverse relation between 
vitamin D and HbA1c which is marker of prolonged 
glycemic status, thus highlighting the possible role of 
vitamin D in glycemic control (HbA1c). On the basis of 
the findings in our study, we suggested, there should be 
a routine screening for vitamin D levels in patients with 
diabetes and patients with diabetes should suplement 
vitamin D in their diet; a plausible way to mitigate the 
impact of VDD in the pathogeneses of T2DM. However, 
long term studies with a larger cohort, investigating the 
effect of supplementation of vitamin D on the incidence 
and glycemic control of T2DM can significantly help to 
drive a conclusive evidence linking those two.
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